Charles Schwab’s Anixa Biosciences ANIX Stock Holding History

Charles Schwab’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.8K	Buy	12,798 +13	+0.1%	+$36	﹤0.01%	3430
2026 Q1	$33K	Hold	12,785	–	–	﹤0.01%	3441
2025 Q4	$39.9K	Hold	12,785	–	–	﹤0.01%	3434
2025 Q3	$42.2K	Hold	12,785	–	–	﹤0.01%	3437
2025 Q2	$42.2K	Hold	12,785	–	–	﹤0.01%	3460
2025 Q1	$36.6K	Hold	12,785	–	–	﹤0.01%	3430
2024 Q4	$29.7K	Hold	12,785	–	–	﹤0.01%	3472
2024 Q3	$40.3K	Hold	12,785	–	–	﹤0.01%	3436
2024 Q2	$28.3K	Hold	12,785	–	–	﹤0.01%	3568
2024 Q1	$39.9K	Hold	12,785	–	–	﹤0.01%	3386
2023 Q4	$49.6K	Hold	12,785	–	–	﹤0.01%	3405
2023 Q3	$41.8K	Hold	12,785	–	–	﹤0.01%	3421
2023 Q2	$40.9K	Hold	12,785	–	–	﹤0.01%	3444
2023 Q1	$55K	Hold	12,785	–	–	﹤0.01%	3334
2022 Q4	$54.3K	Hold	12,785	–	–	﹤0.01%	3338
2022 Q3	$63K	Sell	12,785 -11,431	-47%	-$46.3K	﹤0.01%	3276
2022 Q2	$75K	Buy	+24,216	New	+$76.4K	﹤0.01%	3320

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Charles Schwab's ANIX Position: Q2 2026 in Review

Charles Schwab increased its Anixa Biosciences (ANIX) stake by 0.1% in Q2 2026, buying an estimated $36 and bringing the position to 12,798 shares worth $35.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3430.

Charles Schwab first reported a position in ANIX in Q2 2022 and has held it in 17 quarters since. The position peaked at $75K in Q2 2022. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

Charles Schwab held 12,798 shares of Anixa Biosciences worth $35.8K as of Q2 2026.
Charles Schwab bought 13 Anixa Biosciences shares in Q2 2026, an estimated $36.
Anixa Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3430 holding.
Charles Schwab first reported a position in Anixa Biosciences in Q2 2022 and has held it in 17 quarters since.
Charles Schwab's Anixa Biosciences position peaked at $75K in Q2 2022.
62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.